Morphine

Morphine

SCHEMBL1314201

CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5.O

nearest known ligand 0.98

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

OPRM1

The experimentally established mechanism targets of Morphine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
OPRM1 known ✓ P35372 8/20 0.98
OPRD1 P41143 11/20 0.98
OPRK1 P41145 6/20 0.98
MRGPRX2 Q96LB1 4/20 0.98
SLC22A1 O15245 1/20 0.98
ADRA2A P08913 1/20 0.98
ARRB1 P49407 1/20 0.98
ADRB1 P08588 1/20 0.74
PDE4D Q08499 1/20 0.74
PDE3A Q14432 1/20 0.74

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Morphine SCHEMBL6238952 1.00 OPRD1 (0.98) OPRD1OPRM1OPRK1MRGPRX2SLC22A1
Morphine SCHEMBL29245643 1.00 OPRD1 (0.98) OPRD1OPRM1OPRK1MRGPRX2SLC22A1
Morphine SCHEMBL3369901 1.00 OPRD1 (0.98) OPRD1OPRM1OPRK1MRGPRX2SLC22A1
Morphine SCHEMBL28185924 1.00 OPRD1 (0.98) OPRD1OPRM1OPRK1MRGPRX2SLC22A1
Morphine SCHEMBL31298106 1.00 OPRD1 (0.98) OPRD1OPRM1OPRK1MRGPRX2SLC22A1
Morphine SCHEMBL7532547 1.00 OPRD1 (0.98) OPRD1OPRM1OPRK1MRGPRX2SLC22A1
Morphine SCHEMBL29846325 0.99 OPRD1 (0.96) OPRD1OPRM1OPRK1MRGPRX2SLC22A1
Morphine SCHEMBL14109970 0.99 OPRD1 (0.96) OPRD1OPRM1OPRK1MRGPRX2SLC22A1
Morphine SCHEMBL147362 0.99 OPRD1 (0.96) OPRD1OPRM1OPRK1MRGPRX2SLC22A1
Morphine SCHEMBL24599520 0.99 OPRD1 (1.00) OPRD1OPRM1OPRK1MRGPRX2SLC22A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12529695-B2 Fentanyl analogue detection methods and kits thereof VERITEQUE USA, INC. (US) 2026-01-20 US disclosed
CN-111465396-B Abuse-resistant morphine sulfate dosage form 普渡制药公司 2024-07-09 CN disclosed
US-20220390439-A1 FENTANYL ANALOGUE DETECTION METHODS AND KITS THEREOF VERITEQUE USA, INC. 2022-12-08 US disclosed
EP-4049008-A1 FENTANYL ANALOGUE DETECTION METHODS AND KITS THEREOF Veriteque USA, Inc. (US) 2022-08-31 EP disclosed
WO-2021081063-A1 FENTANYL ANALOGUE DETECTION METHODS AND KITS THEREOF VERITEQUE USA, INC. (US) 2021-04-29 WO disclosed
US-10183001-B1 Opioid and attention deficit hyperactivity disorder medications possessing abuse deterrent and anti-dose dumping safety features PISGAH LABORATORIES, INC. (US) 2019-01-22 US disclosed
US-20150133664-A1 CHEMICAL TRANSFORMATIONS OF (-)-CODEINE TO AFFORD DERIVATIVES OF CODEINE AND MORPHINE THEREOF UNIV TEXAS (US) 2015-05-14 US disclosed
CN-102307876-B Synthesis of morphine-6-glucuronide or one of the derivatives thereof SAI NUOFEI 2014-12-10 CN disclosed
EP-2376496-B1 SYNTHESIS OF MORPHINE-6-GLUCURONIDE OR OF A DERIVATIVE THEREOF SANOFI SA (FR) 2014-03-12 EP disclosed
WO-2013184902-A1 CHEMICAL TRANSFORMATIONS OF (-)-CODEINE TO AFFORD DERIVATIVES OF CODEINE AND MORPHINE THEREOF BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2013-12-12 WO disclosed
US-4376825-A ENZYME-BOUND LIGANDS WITH FREE REACTIVE SITES WHICH CAN BIND RECEPTORS SYVA COMPANY (US) 1983-03-15 US disclosed
US-4282325-A FOR AMPLIFICATION IN ASSAYS SYVA COMPANY (US) 1981-08-04 US disclosed
US-4203802-A ENZYME BOUND TO AN ESTROGEN LIGAND SYVA COMPANY (US) 1980-05-20 US disclosed
US-4190496-A RECEPTOR, LIGAND, AND ENZYME-BOUND SYVA COMPANY (US) 1980-02-26 US disclosed
US-4067774-A Compounds for enzyme amplification assay SYVA COMPANY (US) 1978-01-10 US disclosed
US-4065354-A HAPTENS SYVA COMPANY (US) 1977-12-27 US disclosed
US-4064228-A Antigens and immunoassays for morphine and related 3-oxybenzomorphan compounds BIOLOGICAL DEVELOPMENTS, INC. (US) 1977-12-20 US disclosed
US-4045440-A ETHERIFICATION WITH METHYL IODIDE, OXIDATION WITH MANGANESE DIOXIDE THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH, EDUCATION AND WELFARE (US) 1977-08-30 US disclosed
US-3975237-A LIGANDS SYVA COMPANY (US) 1976-08-17 US disclosed
US-3966556-A Compounds for enzyme amplification assay methadone analogs SYVA COMPANY (US) 1976-06-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10183001-B1 Opioid and attention deficit hyperactivity disorder medications possessing abuse deterrent and anti-dose dumping safety features OPRM1, OPRD1, OPRL1 OPRM1 1/4885OPRD1 2/4885OPRK1 5/4885
US-12529695-B2 Fentanyl analogue detection methods and kits thereof CA13, CA2, CA12 OPRM1 24/4885OPRD1 6/4885OPRK1 19/4885
US-20150133664-A1 CHEMICAL TRANSFORMATIONS OF (-)-CODEINE TO AFFORD DERIVATIVES OF CODEINE AND MORPHINE THEREOF OPRK1, OPRM1, OPRD1 OPRM1 2/4885OPRD1 3/4885OPRK1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.